Enozertinib shows strong efficacy in advanced NSCLC with EGFR atypical mutations, entering Phase 3 trials in 2027. ORIC ...

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today presented ...

A central Arkansas father is fighting for his life and hoping a stranger could be the answer to his prayers as he searches ...

The oral, once-daily EGFR inhibitor is now in specialty distribution for patients whose disease progressed after ...

Annualized eGFR slope of -0.6 vs. -5.7 mL/min/1.73 m²/year for placebo, a 5.1 mL/min/1.73 m²/year treatment difference ...

Vera Therapeutics (Nasdaq: VERA) announced that the final efficacy analysis of its ORIGIN 3 trial for TRUTAKNA (atacicept-vymj) in adults with primary IgA nephropathy (IgAN) met statistical ...

ZEGFROVY is now available in the US for post-platinum EGFR exon 20 insertion NSCLC after a 46% response rate in WU-KONG1B.

Sparsentan lowered blood pressure more than irbesartan at week 8, with mean differences of -7.2 mmHg systolic and -5.6 mmHg diastolic.

AstraZeneca (NYSE: AZN) announced the US availability of Zegfrovy (sunvozertinib), a treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth ...

BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines ...

A retrospective study of 86 patients with advanced urothelial carcinoma found that baseline kidney function, rather than ...

In a cross-sectional study of 240 patients with chronic kidney disease, higher serum BDNF levels and a ...